Venous aneurysms are rare vascular malformations that can lead to significant clinical complications, including thrombosis, pulmonary embolism, rupture, and even fatal outcomes when not promptly and adequately managed. This case report presents a liver transplant patient under immunosuppressive therapy who developed a rapidly progressing great saphenous vein aneurysm, ultimately requiring urgent surgical intervention due to acute bleeding from the ruptured aneurysm. Immunosuppression emerges as a potential key factor in the formation and rapid growth of the aneurysm, with the pathophysiological mechanism potentially involving increased expression of specific matrix metalloproteinases. Further research is warranted to gain a better understanding of the role of immunosuppression in the development of venous aneurysms.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10890480 | PMC |
http://dx.doi.org/10.3390/medicina60020290 | DOI Listing |
J Vasc Bras
January 2025
Souss Massa University Hospital Center, Agadir, Morocco.
Venous aneurysms are uncommon and can involve the entire venous system and occur at any age. The presence of these aneurysmal formations at the level of the saphenous vein junction is rarely reported, given the small number of cases described in the literature. We report the case of a 41-year-old patient with an aneurysm in the saphenofemoral junction of the right great saphenous vein, discovered incidentally during a consultation for varicose veins of the right lower limb.
View Article and Find Full Text PDFAnn Vasc Surg
January 2025
Department of Vascular and Endovascular Surgery - Tertiary Aortic Center, Pitie-Salpêtrière University Hospital, 47-83 Bd de l'Hôpital, Paris, France; Sorbonne Université, Paris, France. Electronic address:
Objective: Chronic limb-threatening ischemia (CLTI) requires revascularization whenever it is possible. The great saphenous vein represents the surgical conduit of choice. However, it is not always available, in particular in multi-operated patients.
View Article and Find Full Text PDFAnn Vasc Surg
January 2025
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia - National Cardiovascular Center Harapan Kita.
Background: Although guidelines have established endovenous laser ablation (EVLA) as the first-line option for patients with varicose veins (VVs) in chronic Great saphenous vein (GSV) insufficiency, however, Chronic Vein Insufficiency (CVI) remains a significant healthcare burden. Endovenous microwave ablation (EMA) is a promising alternative. This review aims to analyze the Endovenous Microwave Ablation versus Endovenous Laser Ablation for Varicose Veins in Chronic Great Saphenous Vein Insufficiency METHODS: Randomized controlled trials (RCTs) and cohort studies across PubMed, Scopus, Science Direct, and the Cochrane Library up to November 11, 2024 was searched.
View Article and Find Full Text PDFCase Rep Surg
January 2025
Division of Vascular Surgery, Department of Surgery, College of Medicine, King Saud University, Riyadh 11322, Saudi Arabia.
Phlebolith is a term that refers to round-shaped calcified thrombi commonly located in the pelvic region. The occurrence of dense, linear calcifications or phlebolith-like formations within the soft tissues of the lower extremities, particularly in the superficial femoral, greater saphenous, or popliteal veins, is rare. This study presents the case of a 73-year-old woman who was being evaluated for postmenopausal bleeding.
View Article and Find Full Text PDFEur J Vasc Endovasc Surg
January 2025
Department of Phlebology, Skin and Vein Clinic Oosterwal, Alkmaar, the Netherlands.
Objective: The aim of this study was to compare anterior accessory saphenous vein (AASV) reflux after standard endovenous laser ablation (EVLA) vs. flush EVLA (fEVLA) of the great saphenous vein (GSV).
Methods: This was as randomised, single blind, controlled trial (Dutch Trial Register, NL5283).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!